|Articles|April 1, 2001
- Pharmaceutical Executive-04-01-2001
- Volume 0
- Issue 0
Regulation: OK After All
Author(s)Kevin Gopal
London-The National Institute of Clinical Excellence (NICE) has decided that Roche's Xenical (orlistat) should be available from the National Health Service for managing obesity and its related problems, but it should not be viewed as a slimming pill.
Advertisement
Articles in this issue
almost 25 years ago
Internet DTC - Minding Your P's & Q'salmost 25 years ago
Regulation: Two-Track Planalmost 25 years ago
Policy: Tectonic Shiftalmost 25 years ago
Liberated?almost 25 years ago
A Matter of Tastealmost 25 years ago
Partnerships: Bargaining Biotechsalmost 25 years ago
Pediatric Mandatealmost 25 years ago
Genentech's Passion for PatientsNewsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
What Pharma Marketers Need to Know About Recent Gartner Predictions About AI and What It Means to Them
2
What Governance Resets Should Pharma Companies Take in Response to AI?
3
FDA Approves Icotyde as Treatment of Moderate-to-Severe Plaque Psoriasis in Adults and Adolescents
4
TrumpRx Selling Medicines at Higher Prices Than Other Countries: Report
5